Related Experiment Video
Updated: May 11, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Determinants of progression of aortic stiffness in hemodialysis patients: a prospective longitudinal study
Mihai S Utescu1, Véronique Couture, Fabrice Mac-Way
1CHU de Québec Research Center, L’Hôtel Dieu de Québec Hospital Quebec, Quebec, Canada.
Insights
Arterial stiffness progresses rapidly in dialysis patients, driven by advanced glycation end products, not traditional risk factors. Baseline stiffness influences brachial stiffness regression.
Area of Science:
- Nephrology
- Cardiology
- Vascular Biology
Background:
- Aortic stiffness is linked to cardiovascular mortality in chronic kidney disease (CKD) patients.
- Longitudinal data on arterial stiffness progression and risk factors in CKD is lacking.
Purpose of the Study:
- To investigate the rate of arterial stiffness progression in hemodialysis patients.
- To identify cardiovascular risk factors influencing this progression.
Main Methods:
- Prospective, longitudinal observational study of 109 hemodialysis patients.
- Carotid-femoral and carotid-radial pulse wave velocity measured at baseline and after 1.2 years.
- Impact of age, cardiovascular disease, diabetes, dialysis vintage, and pentosidine assessed.
Main Results:
- Annual increase in aortic stiffness (carotid-femoral PWV) was 0.84 m/s.
- Brachial stiffness (carotid-radial PWV) showed an annual decrease of -0.66 m/s.
- Plasma pentosidine levels significantly predicted the rate of aortic stiffness progression (P=0.001).
- Baseline stiffness predicted brachial stiffness regression (P<0.001).
Conclusions:
- Arterial stiffness progresses rapidly in dialysis patients.
- Advanced glycation end products, like pentosidine, are key drivers of stiffness progression in CKD.
- CKD-specific factors, rather than traditional ones, appear dominant in this progression.
Abstract:
Aortic stiffness is associated with increased cardiovascular mortality in patients with chronic kidney disease. However, the rate of progression of arterial stiffness and the role of cardiovascular risk factors in the progression of arterial stiffness has never been established in a longitudinal study. In a prospective, longitudinal, observational study, carotid-femoral pulse wave velocity and carotid-radial pulse wave velocity were assessed in 109 hemodialysis patients at baseline and after a mean follow-up of 1.2 years. We examined the impact of age, atherosclerotic cardiovascular disease, diabetes mellitus, dialysis vintage, and pentosidine (a well-characterized, advanced glycation end products) on the rate of progression of aortic stiffness. The annual rate of changes in carotid-femoral pulse wave velocity and carotid-radial pulse wave velocity were 0.84 m/s per year (95% confidence interval, 0.50-1.12 m/s per year) and -0.66 m/s per year (95% confidence interval, -0.85 to -0.47 m/s per year), respectively. Older subjects, and patients with diabetes mellitus or atherosclerotic cardiovascular disease had higher aortic stiffness at baseline, however, the rate of progression of aortic stiffness was only determined by plasma pentosidine levels (P=0.001). The degree of baseline aortic stiffness was a significant determinant of the regression of brachial stiffness (P<0.001) suggesting that the regression of brachial stiffness occurs in response to central aortic stiffness. These findings suggest that traditional cardiovascular risk factors may play some role in the progression of aortic stiffness before development of advanced chronic kidney disease, and that the enhanced rate of progression of aortic stiffness in chronic kidney disease patients on dialysis are probably determined by more specific chronic kidney disease-related risk factors such as advanced-glycation end products.
Related Concept Videos
Hemodialysis II: Procedure and Complications
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Heart Failure II: Pathophysiology
Hemodialysis I: Introduction
Hemodialysis III: Nursing Management
Hypertension II: Pathophysiology

